Register for free to listen to this article
Listen with Speechify
0:00
1:00
GE Healthcare
 
GE Healthcare has launched FTA DMPK cards for the collectionand storage of blood samples for use in pharmacokinetic and toxicokinetic(PK/TK) studies. This methodology stores the samples as dried blood spots (DBS)and has a broad applicability across the entire drug discovery and developmentprocess, from research through to preclinical and clinical trials. The lowerrequired blood volumes of 10 to 20 µl, compared to traditional approachesneeding up to 500 µl, supports serial sampling, leading to enhanced dataconsistency and a reduction in the number of animals required per study. FTADMPK cards deliver both an ethical and economic benefit with workflow timereduced, as the procedure for blood sample processing is greatly simplified.For all card types, the resultant DBS samples can be stored and shipped at roomtemperature, while FTA DMPK-A and FTA DMPK-B cards also inactivate viruses andprevent bacterial contamination, making handling and shipping of samples saferand more straightforward. For analysis, sample discs are taken from the cardsusing a manual or automatic punch, from which the compounds of interest areextracted and analyzed.
 
GE Healthcare
 

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A blue x-ray style image of a human body is shown with the liver illuminated in orange against a dark blue background.

Harnessing liver-on-a-chip models for drug safety

Discover how researchers leverage microphysiological systems in toxicology studies.  
A person wearing a white lab coat types on a laptop with various overlaid enlarged files shown with plus signs on file folders floating over the laptop screen with a clinical lab shown in the background in grey and white tones.

Enhancing bioanalytical studies with centralized data management

Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
A 3D-rendered digital illustration of a molecular structure floating among red blood cells in a bloodstream environment.

Explained: How are metabolite biomarkers improving drug discovery and development?

By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue